Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259936 | 0.80 | NPC1 (0.32) | NPC1RAB9AMGLLSLC6A2SLC6A4 | |
| SCHEMBL8588060 | 0.80 | SLC6A2 (0.31) | HTTSLC6A2SLC6A4SLC6A3PIK3CD | |
| SCHEMBL594792 | 0.76 | NPC1 (0.33) | HTTNPC1ALOX15RAB9AMGLL | |
| SCHEMBL4986617 | 0.76 | NPC1 (0.33) | HTTNPC1ALOX15RAB9AMGLL | |
| SCHEMBL2493301 | 0.76 | NPC1 (0.33) | HTTNPC1ALOX15RAB9AMGLL | |
| SCHEMBL8718896 | 0.76 | HPGD (0.34) | — | |
| SCHEMBL5707591 | 0.75 | NPC1 (0.32) | HTTNPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL5707655 | 0.75 | NPC1 (0.32) | HTTNPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL30751007 | 0.74 | SLC6A2 (0.32) | HTTNPC1RAB9ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL29878392 | 0.73 | SLC6A2 (0.32) | HTTSLC6A2SLC6A4SLC6A3PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157095-A2 | Synthesis of beta-L-2-Deoxy nucleosides | Novartis Ag (CH) | 2010-02-24 | — | — | EP | claimed |
| EP-1639121-A4 | SYNTHESIS OF BETA -L-2-DEOXY NUCLEOSIDES | IDENIX CAYMAN LTD (KY) | 2008-04-16 | — | — | EP | claimed |
| EP-1639121-A2 | SYNTHESIS OF BETA -L-2-DEOXY NUCLEOSIDES | Idenix (Cayman) Limited (KY) | 2006-03-29 | — | — | EP | claimed |
| US-20050059632-A1 | Synthesis of beta-L-2'-deoxy nucleosides | NOVARTIS AG (CH) | 2005-03-17 | — | — | US | claimed |
| WO-2005003374-A2 | SYNTHESIS OF β-L-2-DEOXY NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2005-01-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059632-A1 | Synthesis of beta-L-2'-deoxy nucleosides | DUT, DERA, RNASEL | HTT 1660/4885NPC1 1401/4885ALOX15 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.